Last June, New York State Attorney General Eliot Spitzer sued the maker of an antidepressant for withholding unfavorable information about the safety and effectiveness of a drug. The suit, filed in the New York Supreme Court and settled this summer, claimed that GlaxoSmithKline conducted at least five studies on the use of Paxil in children and adolescents but only published the one study showing a positive effect. This intensified calls for a government-sponsored registry of trials so that doctors would have wider access to clinical trial results. The general bid for transparency now has strong support from medical organizations, most prominently the AMA, and major medical journals. Drug companies have begun setting their own disclosure policies, though some remain skeptical that a mandatory registry is warranted. Panelists at this event will discuss the benefits and unintended negative consequences of various public database scenarios. They will also appraise alternative approaches to the subject of disclosure.